Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective, Randomized, Double-Masked, Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients With Pterygium

NCT03533244 is registered in ClinicalTrials.gov with Allgenesis Biotherapeutics Inc. as lead sponsor.

NCT NCT03533244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03533244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective, Randomized, Double-Masked, Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients With Pterygium
Lead sponsor
Allgenesis Biotherapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 11, 2018
Completion date
October 25, 2019
Enrollment
64 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pterygium